Technology Networks

Technology Networks Technology Networks is a trusted scientific news publication. We explore the science that matters to you and share news, resources and more.

Technology Networks offer today's scientist a single resource that contains unique, engaging, and entertaining content from their field of research. Thank you for reading, here are a few ground rules when interacting with our content: https://www.technologynetworks.com/tn/editorial-policies

High failure rates for cancer drugs stem from early-stage biological data that lacks predictive power, often due to inco...
22/05/2026

High failure rates for cancer drugs stem from early-stage biological data that lacks predictive power, often due to incomplete datasets or models that fail to capture complex human tumor biology.

Researchers are working to integrate high-quality multi-omics data and advanced AI tools to build more translatable models that better reflect real-world patient responses.

Read more: https://bit.ly/43arKYZ

Will your antibody-drug conjugate translate from in vitro to in vivo?In this webinar, you will learn how to evaluate the...
22/05/2026

Will your antibody-drug conjugate translate from in vitro to in vivo?

In this webinar, you will learn how to evaluate the mechanism of action and more in antibody-drug conjugate discovery, through practical examples and case studies.

đź“… June 2 at 9am ET

Save your place: https://bit.ly/4uo8cfr

Individuals with celiac disease can experience significant anxiety and social hesitation regarding romantic intimacy, fe...
21/05/2026

Individuals with celiac disease can experience significant anxiety and social hesitation regarding romantic intimacy, fearing that kissing a partner who has recently consumed gluten could trigger an autoimmune reaction.

In a first-of-its-kind study, researchers found that while low levels of gluten can be transferred during kissing, this can be easily reduced to safe levels by drinking a little water first.

Read more: https://bit.ly/4nLRN1Z

21/05/2026

Bridging the gap between discovery plasma proteomics and clinically actionable protein measurements remains a major challenge in proteomics research.

In this episode of Teach Me in 10, Dr. Fredrik Edfors discusses why relative protein signals are difficult to compare across cohorts, laboratories, and time.

Type 1 diabetes requires lifelong insulin therapy. We spoke with NextCell about ProTrans, a mesenchymal stem cell therap...
20/05/2026

Type 1 diabetes requires lifelong insulin therapy.

We spoke with NextCell about ProTrans, a mesenchymal stem cell therapy designed preserve insulin production for over six years with just a single dose.

Read more: https://bit.ly/4eUhNG3

Despite being celebrated as a miracle drug, GLP-1s have high costs, uncomfortable side effects, and high levels of disco...
19/05/2026

Despite being celebrated as a miracle drug, GLP-1s have high costs, uncomfortable side effects, and high levels of discontinuation.

Researchers are turning to AI-enabled platforms and simulation models to develop next-generation GPCR-targeted therapies that offer improved selectivity, better tolerability, and more personalized treatment options for obesity.

Read more: https://bit.ly/4wC44tI

18/05/2026

Managing real-time PCR data consistently and compliantly is becoming increasingly complicated. And analysis software is a key but often overlooked part of the equation.

In this Teach Me in 10 episode, Dr. Irene Sarkar explains how a unified real-time PCR detection software platform automates analysis and reporting.

Protein purification is often deceptively complex.In this guide, discover practical insights, optimizations, and trouble...
18/05/2026

Protein purification is often deceptively complex.

In this guide, discover practical insights, optimizations, and troubleshooting tactics that streamline workflows.

Download your copy: https://bit.ly/4wqEJTL

Traditional Alzheimer’s drug development is hindered by high costs, frequent clinical failures, and a reliance on sympto...
17/05/2026

Traditional Alzheimer’s drug development is hindered by high costs, frequent clinical failures, and a reliance on symptom management rather than prevention.

Acta Pharmaceuticals' chief scientific officer describes how his team uses the brain organoid Alzheimer’s-in-a-Dish™ to test gamma-secretase modulators to prevent disease by reducing toxic amyloid-beta while boosting neuroprotective proteins.

Read more: https://bit.ly/3RbTMAp

Chronic accumulation of senescent cells drives tissue dysfunction and age-related disease by disrupting cellular metabol...
16/05/2026

Chronic accumulation of senescent cells drives tissue dysfunction and age-related disease by disrupting cellular metabolism and circadian rhythms.

A new study investigated repurposing the drug vutiglabridin to target mitochondrial pathways and oxidative stress, effectively reversing senescence markers and restoring cellular health.

Read more: https://bit.ly/43hr3wF

How can evolving cell sorting approaches support reproducibility and sterility? In this webinar, gain practical insights...
16/05/2026

How can evolving cell sorting approaches support reproducibility and sterility?

In this webinar, gain practical insights into balancing cell viability, safety, and performance.

📆 May 27 at 10AM ET

Save your place: https://bit.ly/4nxPoYC

Address

Sudbury
Suffolk
CO100FD

Telephone

+441787319234

Website

Alerts

Be the first to know and let us send you an email when Technology Networks posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Share